Related Experiment Video
Updated: Mar 1, 2026
Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Prophylactic Early Erythropoietin for Neuroprotection in Preterm Infants: A Meta-analysis
Hendrik S Fischer1, Nora J Reibel1, Christoph Bührer1
1Department of Neonatology, Charité University Medical Center, Berlin, Germany.
Insights
Prophylactic recombinant human erythropoietin (rhEPO) improved cognitive development in very preterm infants. This neuroprotective agent, rhEPO, showed a significant reduction in developmental delays at 18-24 months corrected age.
Area of Science:
- Neonatal Medicine
- Neuroscience
- Pharmacology
Background:
- Recombinant human erythropoietin (rhEPO) is explored for its neuroprotective potential in newborns.
- Preterm infants face significant risks of neurodevelopmental impairments.
Purpose of the Study:
- To evaluate the efficacy of prophylactic rhEPO in improving neurodevelopmental outcomes for very preterm infants.
- This meta-analysis synthesized data from randomized controlled trials (RCTs).
Main Methods:
- Searched Medline, Embase, and Cochrane Register up to December 2016.
- Included RCTs comparing rhEPO to controls in preterm infants, reporting neurodevelopmental outcomes at 18-24 months corrected age.
- Primary outcome: Mental Developmental Index (MDI) <70; Secondary outcomes: Psychomotor Development Index, cerebral palsy, visual/hearing impairment.
Main Results:
- Four RCTs with 1133 infants were analyzed.
- Prophylactic rhEPO significantly reduced the incidence of MDI <70 (OR 0.51; 95% CI 0.31-0.81; P < .005).
- Number needed to treat was 14; no significant effects on secondary neurodevelopmental outcomes were observed.
Conclusions:
- Prophylactic rhEPO administration enhances cognitive development in very preterm infants.
- Further research is needed to determine optimal rhEPO dosing, timing, and long-term follow-up strategies.
Context:
Recombinant human erythropoietin (rhEPO) is a promising pharmacological agent for neuroprotection in neonates.
Objective:
To investigate whether prophylactic rhEPO administration in very preterm infants improves neurodevelopmental outcomes in a meta-analysis of randomized controlled trials (RCTs).
Data Sources:
Medline, Embase, and the Cochrane Central Register of Controlled Trials were searched in December 2016 and complemented by other sources.
Study Selection:
RCTs investigating the use of rhEPO in preterm infants versus a control group were selected if they were published in a peer-reviewed journal and reported neurodevelopmental outcomes at 18 to 24 months' corrected age.
Data Extraction:
Data extraction and analysis followed the standard methods of the Cochrane Neonatal Review Group. The primary outcome was the number of infants with a Mental Developmental Index (MDI) <70 on the Bayley Scales of Infant Development. Secondary outcomes included a Psychomotor Development Index <70, cerebral palsy, visual impairment, and hearing impairment.
Results:
Four RCTs, comprising 1133 infants, were included in the meta-analysis. Prophylactic rhEPO administration reduced the incidence of children with an MDI <70, with an odds ratio (95% confidence interval) of 0.51 (0.31-0.81), P < .005. The number needed to treat was 14. There was no statistically significant effect on any secondary outcome.
Conclusions:
Prophylactic rhEPO improved the cognitive development of very preterm infants, as assessed by the MDI at a corrected age of 18 to 24 months, without affecting other neurodevelopmental outcomes. Current and future RCTs should investigate optimal dosing and timing of prophylactic rhEPO and plan for long-term neurodevelopmental follow-up.
More Related Videos
05:52Early Pathological and Magnetic Resonance Detection of Cerebral Injury Using a Rat Model of Neonatal Hypoxic Ischemic Encephalopathy
Published on: October 28, 2022
05:15Author Spotlight: Assessing the Feasibility of Using Amplitude-Integrated EEG During Neonatal Transport
Published on: June 21, 2024